The Journal of the American Chemical Society (JACS) has retracted three articles that had earned expressions of concern by chemistry researchers who were under investigation at the University of Texas, Austin.
For one of the comments on the site, the judge has asked to hold another hearing on March 19.
After the work of Fazlul Sarkar of Wayne State University appeared on the post-publication peer review site, he wasn’t happy about it. In October, he sued the site’s commenters, demanding that PubPeer release the names of his accusers. Sarkar, who has not been found to have committed research misconduct, claims he lost a lucrative job offer at the University of Mississippi as a result of the posts.
In December, PubPeer’s attorneys asked the judge to dismiss the motion; today, Hon. Sheila Ann Gibson of the Wayne County Circuit Court agreed to do so for all but one comment.
PLoS ONE has just issued a 12-figure correction on a paper by Mario A. Saad, who sued the American Diabetes Association unsuccessfully in an attempt to prevent it from retracting four papers in its flagship journal Diabetes.
The corrections include taking out Western blots copied from another Saad paper, as well as several figures where the bands were “misplaced.”
Both retractions appear in the Journal of Clinical Endocrinology & Metabolism. The notices indicate that an investigation report from the University of Florida “found substantial data misrepresentation” in two JCEM articles about Smads, signaling molecules that carry messages from TGF-beta receptors to the nucleus.
Here’s the notice for “The Expression of Smads in Human Endometrium and Regulation and Induction in Endometrial Epithelial and Stromal Cells by Transforming Growth Factor-Beta” (cited 28 times, according to Thomson Scientific’s Web of Knowledge):
David Vaux, a cell biologist at the Walter + Eliza Hall Institute of Medical Research in Melbourne, explains how Nature could do more to remove bias from the peer review process. He previously wrote about his decision to retract a paper.
David Vaux
Last week, Nature announced that they are to offer authors of papers submitted to Nature or the monthly Nature research journals the option of having their manuscripts assessed by double-blind peer review, in which reviewers are blinded to the identity of authors and their institutions. Until now, papers sent to Nature, and most other journals, have been reviewed by a single-blind process, in which the reviewers know the identities and affiliations of the authors, but the authors are not told who the reviewers are. The goal of double-blind peer review is for submitted papers to be judged on their scientific merit alone, and thus to reduce publication bias.
While Nature should be applauded for this move, the way they have implemented it leaves room for improvement.
As reported by the National Law Journal, a federal judge in Boston has denied Saad’s requests to stop the ADA’s flagship journal, Diabetes, from publishing expressions of concern about four of Saad’s papers, and to prevent the journal from retracting the studies.
The authors of a 2011 Science paper that proposed a new way to direct chemical bonds have withdrawn the paper after concerns about the data prompted an investigation and Editorial Expression of Concern last year from the journal. The retraction is the second for the group, which has also had seven other expressions of concern.
After a reader emailed the editors to raise suspicions about the data, corresponding author Christopher W. Bielawski, then based at the University of Texas at Austin, led an investigation of all the figures. It found substantial problems: “In over 50% of the figure parts, the authors deemed the data unreliable due to uncertainty regarding the origin of data or the manner in which the data were processed,” according to the retraction notice.
UT Austin concluded that there had been misconduct, but did not elaborate.